Fly News Breaks for January 31, 2020
Jan 31, 2020 | 08:12 EDT
JPMorgan analyst Jessica Fye downgraded Intra-Cellular Therapies to Neutral from Overweight with a price target of $26, up from $19. While Caplyta for schizophrenia is differentiated in its safety profile versus other antipsychotics and should see a complete national launch from the start with many formulary reviews expected to occur in the first nine months, the 2020 consensus estimate of ~$50M sets a bar that will be difficult to meet, Fye tells investors in a research note. As such, the analyst sees risk for downward estimate revisions based on initial script trends. Further, the company's approaching bipolar depression readout "could break either way," contends Fye.
News For ITCI From the Last 2 Days
There are no results for your query ITCI